Welcome to Needham

Needham & Company, LLC, a subsidiary of The Needham Group, Inc., is a nationally recognized investment banking and asset management firm focused solely on growth companies and their investors. Needham’s mission is to provide its clients with the long-term advice they need to achieve their business goals. The Firm's commitment to exceptional service is unusual in today’s business climate, and is born of a tradition which stresses integrity above all else. We strive to be front of mind, approachable and idea driven. Needham is actively engaged in the public and private capital markets, boasting a 30-year track record of executing complex transactions and the accompanying reputation for excellence in our markets.

Needham’s principal activities involve assisting our clients through a variety of advisory and transaction-related services, with a specific focus on:




  • 3D Systems (NYSE:DDD) is pioneering 3D design and fabrication for everyone. 3DS provides the most advanced and comprehensive solutions including 3D printers, print materials and cloud sourced custom parts. Its powerful ecosystem empowers professionals and consumers everywhere to bring their ideas to life in material choices including plastics, metals, ceramics and edibles. 3DS' leading 3D healthcare solutions include end-to-end simulation, training and planning and printing of surgical instruments and devices for personalized surgery and patient specific medical and dental devices. Its democratized 3D digital design, fabrication and inspection products provide seamless interoperability between subtractive and additive manufacturing and incorporate the latest immersive computing technologies. Its products and services replace and complement traditional methods with improved results and reduced time to outcomes. These solutions are used to rapidly design, create, communicate, plan, guide, prototype or produce functional parts, devices and assemblies, empowering customers to manufacture the future.

    3D Systems (NYSE:DDD), is a leading global provider of 3D content-to-print solutions including 3D printers, print materials and on-demand custom parts services for professionals and consumers alike announced that it has completed the acquisition of Cimatron Ltd. (Nasdaq:CIMT), a leading provider of integrated CAD/CAM software solutions for the toolmaking and manufacturing industries for approximately $97 million, inclusive of Cimatron's net cash. Needham & Company served as exclusive financial advisor to 3D Systems on this transaction.

  • Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and other diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). OCA has received breakthrough therapy designation from the FDA for the treatment of NASH with fibrosis. OCA has also received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan, China and Korea, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma.

    Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) raised $202.4 million in its follow-on offering at $176.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 150,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Intercept Pharmaceuticals for additional funding of ongoing clinical trials, general corporate purposes including working capital and operating expenses.

  • BTU International, Inc. (NASDAQ: BTUI) is global supplier and technology leader of advanced thermal processing equipment and processes to the electronics and alternative energy manufacturing markets. BTU equipment is used in the production of printed circuit board assemblies and semiconductor packaging as well as in solar cell and nuclear fuel manufacturing.

    BTU International, Inc. (NASDAQ: BTUI), a global supplier of advanced thermal processing equipment to the electronics and alternative energy manufacturing markets, completed its previously announced sale to Amtech Systems, Inc. (NASDAQ: ASYS), a global supplier of production and automation systems and related supplies for the manufacture of solar cells, semiconductors, and sapphire and silicon wafers. Under the terms of the merger agreement, BTU shareholders received 0.3291 shares of Amtech common stock per share of BTU common stock. The transaction valued BTU at approximately $26.2 million based on Amtech’s close price on Friday, January 30, 2015. Needham & Company acted as exclusive financial advisor to BTU International on the transaction.

  • NeuLion, Inc. (TSX: NLN) offers the true end-to-end solution for delivering live and on-demand content to Internet-enabled devices. NeuLion enables content owners and distributors, cable operators and telecommunications companies to capitalize on the massive consumer demand for viewing video content on PCs, smartphones, iPads and other similar devices. NeuLion's customers include major entertainment, sports, global content and news companies. NeuLion is based in Plainview, NY.

    NeuLion, Inc. (TSX: NLN), the leading enabler and provider of live and on-demand content to Internet-connected devices, announced that it has completed the acquisition of DivX Corporation, a leading provider of next-generation digital video solutions. The total transaction value is approximately $62.5 million. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of NeuLion, Inc. as part of its services.

  • Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.

    Omeros Corporation (NASDAQ: OMER) raised $84 million in its follow-on offering at $20.03 per share of its common stock at a per share price to the public equal to $20.03, and pre-funded warrants to purchase up to 749,250 shares of its common stock, at a per warrant price to the public equal to $20.02. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 449,325 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Omeros Corporation for general corporate purposes, including expenses related to the commercialization of Omidria™, research and development expenses, such as funding clinical trials, preclinical studies, manufacturing development and costs associated with otherwise advancing the company's drug candidates toward New Drug Application submission. Omeros may also use the net proceeds for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to its own, and other capital expenditures.

  • TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) develops targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies.

    TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) raised $36 million in its initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by TRACON Pharmaceuticals for additional funding of ongoing clinical trials, general corporate purposes including working capital and operating expenses.

  • Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam’s pipeline of investigational RNAi therapeutics is focused in 3 Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases.

    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) raised $517.5 million in its follow-on offering at $95 per share. Needham acted as the co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 710,526 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Alnylam Pharmaceuticals for general corporate purposes, focused on achieving its Alnylam 2020 profile with 3 marketed products, 10 RNAi therapeutic clinical programs, including 4 in late stages of development, across its 3 Strategic Therapeutic Areas, or “STArs” – Genetic Medicines, Cardio-Metabolic Disease, and Hepatic Infectious Disease – by the end of 2020.

  • Sanbolic is an innovator and leader in workload-oriented storage virtualization technologies. Sanbolic technology enables customers to software-define storage to optimize the delivery of application-specific workloads, from any media type – SSD, Flash and hard drives in NAS, SAN, server-side and cloud deployments – improving storage load balancing, application availability and delivering the highest-performance end-user experience.

    Sanbolic, an innovator and leader in workload-oriented storage virtualization technologies, completed its previously announced sale to Citrix Systems, Inc. (NASDAQ: CTXS), a leader in mobile workspaces, providing virtualization, mobility management, networking and cloud services to enable new ways to work better. The terms of the acquisition were not disclosed. Needham & Company served as exclusive financial advisor to Sanbolic on this transaction.

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/a

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • 3D Systems (NYSE:DDD) is pioneering 3D design and fabrication for everyone. 3DS provides the most advanced and comprehensive solutions including 3D printers, print materials and cloud sourced custom parts. Its powerful ecosystem empowers professionals and consumers everywhere to bring their ideas to life in material choices including plastics, metals, ceramics and edibles. 3DS' leading 3D healthcare solutions include end-to-end simulation, training and planning and printing of surgical instruments and devices for personalized surgery and patient specific medical and dental devices. Its democratized 3D digital design, fabrication and inspection products provide seamless interoperability between subtractive and additive manufacturing and incorporate the latest immersive computing technologies. Its products and services replace and complement traditional methods with improved results and reduced time to outcomes. These solutions are used to rapidly design, create, communicate, plan, guide, prototype or produce functional parts, devices and assemblies, empowering customers to manufacture the future.

    3D Systems (NYSE:DDD), is a leading global provider of 3D content-to-print solutions including 3D printers, print materials and on-demand custom parts services for professionals and consumers alike announced that it has completed the acquisition of Cimatron Ltd. (Nasdaq:CIMT), a leading provider of integrated CAD/CAM software solutions for the toolmaking and manufacturing industries for approximately $97 million, inclusive of Cimatron's net cash. Needham & Company served as exclusive financial advisor to 3D Systems on this transaction.

  • Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and other diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). OCA has received breakthrough therapy designation from the FDA for the treatment of NASH with fibrosis. OCA has also received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan, China and Korea, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma.

    Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) raised $202.4 million in its follow-on offering at $176.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 150,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Intercept Pharmaceuticals for additional funding of ongoing clinical trials, general corporate purposes including working capital and operating expenses.

  • BTU International, Inc. (NASDAQ: BTUI) is global supplier and technology leader of advanced thermal processing equipment and processes to the electronics and alternative energy manufacturing markets. BTU equipment is used in the production of printed circuit board assemblies and semiconductor packaging as well as in solar cell and nuclear fuel manufacturing.

    BTU International, Inc. (NASDAQ: BTUI), a global supplier of advanced thermal processing equipment to the electronics and alternative energy manufacturing markets, completed its previously announced sale to Amtech Systems, Inc. (NASDAQ: ASYS), a global supplier of production and automation systems and related supplies for the manufacture of solar cells, semiconductors, and sapphire and silicon wafers. Under the terms of the merger agreement, BTU shareholders received 0.3291 shares of Amtech common stock per share of BTU common stock. The transaction valued BTU at approximately $26.2 million based on Amtech’s close price on Friday, January 30, 2015. Needham & Company acted as exclusive financial advisor to BTU International on the transaction.

  • NeuLion, Inc. (TSX: NLN) offers the true end-to-end solution for delivering live and on-demand content to Internet-enabled devices. NeuLion enables content owners and distributors, cable operators and telecommunications companies to capitalize on the massive consumer demand for viewing video content on PCs, smartphones, iPads and other similar devices. NeuLion's customers include major entertainment, sports, global content and news companies. NeuLion is based in Plainview, NY.

    NeuLion, Inc. (TSX: NLN), the leading enabler and provider of live and on-demand content to Internet-connected devices, announced that it has completed the acquisition of DivX Corporation, a leading provider of next-generation digital video solutions. The total transaction value is approximately $62.5 million. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of NeuLion, Inc. as part of its services.

  • Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.

    Omeros Corporation (NASDAQ: OMER) raised $84 million in its follow-on offering at $20.03 per share of its common stock at a per share price to the public equal to $20.03, and pre-funded warrants to purchase up to 749,250 shares of its common stock, at a per warrant price to the public equal to $20.02. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 449,325 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Omeros Corporation for general corporate purposes, including expenses related to the commercialization of Omidria™, research and development expenses, such as funding clinical trials, preclinical studies, manufacturing development and costs associated with otherwise advancing the company's drug candidates toward New Drug Application submission. Omeros may also use the net proceeds for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to its own, and other capital expenditures.

  • TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) develops targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies.

    TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) raised $36 million in its initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by TRACON Pharmaceuticals for additional funding of ongoing clinical trials, general corporate purposes including working capital and operating expenses.

  • Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam’s pipeline of investigational RNAi therapeutics is focused in 3 Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases.

    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) raised $517.5 million in its follow-on offering at $95 per share. Needham acted as the co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 710,526 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Alnylam Pharmaceuticals for general corporate purposes, focused on achieving its Alnylam 2020 profile with 3 marketed products, 10 RNAi therapeutic clinical programs, including 4 in late stages of development, across its 3 Strategic Therapeutic Areas, or “STArs” – Genetic Medicines, Cardio-Metabolic Disease, and Hepatic Infectious Disease – by the end of 2020.

  • Sanbolic is an innovator and leader in workload-oriented storage virtualization technologies. Sanbolic technology enables customers to software-define storage to optimize the delivery of application-specific workloads, from any media type – SSD, Flash and hard drives in NAS, SAN, server-side and cloud deployments – improving storage load balancing, application availability and delivering the highest-performance end-user experience.

    Sanbolic, an innovator and leader in workload-oriented storage virtualization technologies, completed its previously announced sale to Citrix Systems, Inc. (NASDAQ: CTXS), a leader in mobile workspaces, providing virtualization, mobility management, networking and cloud services to enable new ways to work better. The terms of the acquisition were not disclosed. Needham & Company served as exclusive financial advisor to Sanbolic on this transaction.

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/a

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A